Allergy Therapeutics Financial Flexibility Index
Allergy Therapeutics financial flexibility index. Allergy Therapeutics (AGY) has a Financial Flexibility Index of -0.13x as of December 2025. Free cash flow of GBX-8.90 Million (operating CF GBX-11.71 Million minus capex GBX2.81 Million) represents 0% of total liabilities (GBX66.75 Million). See AGY cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of Allergy Therapeutics (2002–2025)
Financial flexibility index of Allergy Therapeutics from 2002 to 2025. Historical Financial Flexibility Index trend for Allergy Therapeutics across 24 annual periods. Check Allergy Therapeutics cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Allergy Therapeutics Financial Flexibility Index by Year (2002–2025)
Allergy Therapeutics financial flexibility index by year from 2002 to 2025. Year-by-year free cash flow to debt coverage for Allergy Therapeutics. For the full cash flow conversion analysis, see cash efficiency ratio of Allergy Therapeutics.
| Year | Flexibility Index | Free Cash Flow (GBX) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -0.27x | GBX-25.45 Million | GBX-28.72 Million | GBX95.74 Million | ▲ +43.5% |
| 2024 | -0.47x | GBX-28.74 Million | GBX-32.14 Million | GBX61.12 Million | ▼ -15.9% |
| 2023 | -0.41x | GBX-26.25 Million | GBX-30.92 Million | GBX64.70 Million | ▼ -29.1% |
| 2022 | -0.31x | GBX-11.05 Million | GBX-14.11 Million | GBX35.18 Million | ▼ -212.2% |
| 2021 | 0.28x | GBX11.08 Million | GBX8.52 Million | GBX39.55 Million | ▼ -19.8% |
| 2020 | 0.35x | GBX14.82 Million | GBX12.28 Million | GBX42.44 Million | ▲ +28.5% |
| 2019 | 0.27x | GBX8.41 Million | GBX5.60 Million | GBX30.94 Million | ▲ +523.3% |
| 2018 | -0.06x | GBX-1.80 Million | GBX-3.80 Million | GBX27.98 Million | ▼ -204.2% |
| 2017 | 0.06x | GBX1.68 Million | GBX178.00K | GBX27.22 Million | ▲ +115.3% |
| 2016 | -0.40x | GBX-10.61 Million | GBX-11.84 Million | GBX26.36 Million | ▼ -255.0% |
| 2015 | 0.26x | GBX4.21 Million | GBX3.12 Million | GBX16.23 Million | ▲ +12.6% |
| 2014 | 0.23x | GBX3.07 Million | GBX2.17 Million | GBX13.32 Million | ▲ +1.3% |
| 2013 | 0.23x | GBX3.25 Million | GBX2.43 Million | GBX14.29 Million | ▼ -27.7% |
| 2012 | 0.31x | GBX4.14 Million | GBX2.88 Million | GBX13.16 Million | ▲ +1234.3% |
| 2011 | -0.03x | GBX-790.00K | GBX-2.03 Million | GBX28.48 Million | ▼ -120.6% |
| 2010 | 0.13x | GBX3.40 Million | GBX1.70 Million | GBX25.23 Million | ▲ +376.1% |
| 2009 | 0.03x | GBX1.28 Million | GBX-440.00K | GBX45.25 Million | ▲ +105.8% |
| 2008 | -0.48x | GBX-16.70 Million | GBX-19.32 Million | GBX34.47 Million | ▲ +52.7% |
| 2007 | -1.02x | GBX-15.77 Million | GBX-18.88 Million | GBX15.40 Million | ▲ +10.3% |
| 2006 | -1.14x | GBX-5.91 Million | GBX-8.10 Million | GBX5.18 Million | ▼ -987.3% |
| 2005 | 0.13x | GBX846.00K | GBX-57.00K | GBX6.58 Million | ▼ -79.9% |
| 2004 | 0.64x | GBX2.67 Million | GBX1.91 Million | GBX4.16 Million | ▲ +43.6% |
| 2003 | 0.45x | GBX2.50 Million | GBX2.10 Million | GBX5.60 Million | ▲ +474.0% |
| 2002 | -0.12x | GBX-1.68 Million | GBX-2.01 Million | GBX14.07 Million | — |